Prior Radiation in Subjects Who Were Treated With Toca 511 and Toca FC Across 3 Toca 511 Phase 1 Trials

被引：0
|
作者：
Cloughesy, T. F. [1 ]
Aghi, M. [2 ]
Bota, D. [3 ]
Chen, C. [4 ]
Elder, J. B. [5 ]
Kalkanis, S. N. [6 ]
Kaptain, G. J. [7 ]
Kesari, S. [8 ,9 ]
Landolfi, J. [10 ]
Mikkelsen, T. [6 ]
Portnow, J. [11 ]
Robbins, J. M. [12 ]
Ostertag, D. [12 ]
Chu, A. [12 ]
Huang, T. [12 ]
Vogelbaum, M. A. [13 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] UCSF, San Francisco, CA USA
[3] UCI, Irvine, CA USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[8] Univ Calif San Diego, San Diego, CA USA
[9] John Wayne Canc Inst, Santa Monica, CA USA
[10] JFK Med Ctr, Edison, NJ USA
[11] City Hope Natl Med Ctr, Duarte, CA USA
[12] Tocagen Inc, San Diego, CA USA
[13] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.758
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2160
引用
收藏
页码：E66 / E67
页数：2
相关论文
共 50 条
  • [41] NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Pugh, Stephanie
    Ellingson, Benjamin
    Kotecha, Rupesh
    Cloughesy, Timothy
    Vogelbaum, Michael
    Aldapec, Kenneth
    Cu, Yunfeng
    Armstrong, Terri
    Mehta, Minesh
    NEURO-ONCOLOGY, 2019, 21 : 220 - 221
  • [42] COMBINATION TOCA 511 & 5-FC SIGNIFICANTLY EXTENDS SURVIVAL IN A MURINE ORTHOTOPIC MODEL OF IN rRACEREBELLAR MEDULLOBLAS TOMA
    Richardson, Angela
    Collins, Sara
    Inagaki, Akhito
    Armstrong, Valerie
    Roussel, Martine
    Robbins, David
    Ayad, Nagy
    Jolly, Douglas
    Kasahara, Noriyuki
    NEURO-ONCOLOGY, 2019, 21 : 120 - 120
  • [43] INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584)
    Aghi, Manish
    Vogelbaum, Michael A.
    Kesari, Santosh
    Chen, Clark C.
    Liau, Linda M.
    Piccioni, David
    Portnow, Jana
    Chang, Susan
    Robbins, Joan M.
    Boyce, Tammy
    Huang, Tiffany T.
    Pertschuk, Dan
    Ostertag, Derek
    Cloughesy, Timothy F.
    NEURO-ONCOLOGY, 2014, 16
  • [44] Toca 511 and 5-FC in Combination with Metronomic Cyclophosphamide Reduces Treg Cells and Enhances Therapy Efficacy in a Preclinical Murine Model
    Montellano, Tiffany T.
    Viaud, Sophie
    Mendoza, Daniel
    Rodriguez-Aguirre, Maria
    Gruber, Harry
    Jolly, Douglas
    Ostertag, Derek
    JOURNAL OF NEUROSURGERY, 2019, 131 (01)
  • [45] Mechanism of Action of a Retroviral Replicating Vector, TOCA 511 & 5-FC: Levels of Infection for Anti-Tumor Activity and Immunity
    Yagiz, Kader
    Hofacre, Andrew
    Lin, Amy
    Lopez-Espinoza, Fernando
    Mendoza, Daniel
    Munday, Anthony
    Mitchell, Leah
    Jolly, Douglas J.
    MOLECULAR THERAPY, 2017, 25 (05) : 58 - 59
  • [46] Therapeutic efficacy of anti-tumor immune responses activated by Toca 511/5-FC treatment in pancreatic cancer model
    Niwa, Hiroki
    Nakamura, Toru
    Kushiya, Hiroki
    Inoko, Kazuho
    Hiraoka, Kei
    Inagaki, Akihito
    Tsuchikawa, Takahiro
    Shichinohe, Toshiaki
    Jolly, Douglas
    Kasahara, Noriyuki
    Hirano, Satoshi
    CANCER SCIENCE, 2021, 112 : 808 - 808
  • [47] Interim Report from Two Ongoing Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High Grade Glioma
    Jolly, Douglas J.
    Ibanez, Carlos
    Robbins, Joan M.
    Ostertag, Derek
    Kasahara, Noriyuki
    Aghi, Manish K.
    Vogelbaum, Michael A.
    Bankiewicz, Krystof
    Cloughsey, Timothy F.
    Liau, Linda M.
    Chang, Susan M.
    Butowski, Nicholas
    Kesari, Santosh
    Chen, Clark
    Mikkelsen, Tom
    Kalkanis, Steven N.
    Landolfi, Joseph C.
    Bloomfield, Stephen M.
    Elder, J. Bradley
    Gruber, Harry E.
    Pertschuk, Daniel
    MOLECULAR THERAPY, 2014, 22 : S11 - S11
  • [48] "Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma
    Strebe, Joslyn K.
    Lubin, Jonathan A.
    Kuo, John S.
    NEUROSURGERY, 2016, 79 (06) : N18 - N20
  • [49] Toca 511/5-FC Treatment Has the Potential to Increase the Therapeutic Efficacy of Anti-PD-1 Antibody in an Immunocompetent Murine Pancreatic Cancer Model
    Niwa, Hiroki
    Nakamura, Toru
    Kushiya, Hiroki
    Suzuki, Tomohiro
    Inoko, Kazuho
    Hiraoka, Kei
    Inagaki, Akihito
    Tsuchikawa, Takahiro
    Shichinohe, Toshiaki
    Noriyuki, Kasahara
    Hirano, Satoshi
    MOLECULAR THERAPY, 2023, 31 (04) : 298 - 298
  • [50] ENHANCED THERAPEUTIC EFFICACY OF PRODRUG ACTIVATOR GENE THERAPY WITH A NON-LYTIC RETROVIRAL REPLICATING VECTOR (TOCA 511) COMBINED WITH RADIATION THERAPY IN EXPERIMENTAL GLIOMA
    Takahashi, Masamichi
    Valdes, Gilmer
    Inagaki, Akihito
    Kamijima, Shuichi
    Hiraoka, Kei
    Micewicz, Ewa
    McBride, William H.
    Iwamoto, Keisuke S.
    Hermann, Kip
    Collins, Sara
    Tam, Quincy
    Gruber, Harry E.
    Robbins, Joan M.
    Jolly, Douglas J.
    Kasahara, Noriyuki
    NEURO-ONCOLOGY, 2014, 16
12345